Full index of posts »
StockTalks
-
ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen Nov 30, 2011
-
Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL) Oct 26, 2011
Latest Comments
-
Uncle Bud on Athersys (ATHX) Q1/13 Results – SELL Until It Settles And Then Re-enter! If anyone knows where Gil is coming from It's m...
-
astmshareholder on Aastrom (ASTM) CEO Retires If Tim had issues with the 70-80 hours per week...
-
Noreika on Advanced Cell Technology (OTC BB: ACTC) Settles Of Investor Litigation With Payout Plan Henry, you're bearish on this ACTC news?I'd lik...
-
Noreika on Athersys (ATHX), Rape, Pillage And Plunder – SELL! Henry, do you plan on doing an article on ACTC?...
-
JOHNMIKE118 on Earnings Report Card, Q2/12, Regenerative Medicine Universe This is incredible , Stem Cell is the ONLY rege...
Most Commented
- Updating,ThermoGenesis (KOOLD) (4 Comments)
- Earnings Report Card, Q2/12, Regenerative Medicine Universe (3 Comments)
- 1 for 8 Reverse Stock Split, Aastrom Biosciences (NASDAQ: ASTM) (2 Comments)
- 1 for 4 Reverse Split, ThermoGenesis (KOOL) (1 Comment)
- Aastrom (ASTM) CEO Retires (1 Comment)
Posts by Themes
Financial considerations of the agreement include development and commercial milestone payments to Opexa of up to $195 M and a tiered royalty rate from the high single digits to the mid-teens based on net sales payable to Opexa. The potential payments to,
Financings seem to always set a downward motion to the share pricing – expect a 5-10 depreciation.,
I have maintained a “BUY” in this market and at this pricing because of the late stage trial status even with a dwindling RegMed universe pricing and visibility. As the BOD … fulfills its responsibility … they will make this appointment permanent in the ,
I project a $0.10 to $0.20 jump for SGMO even in a DOWN and vacation weekend market on the non-dilutive CIRM funding – it might even spill over into Tuesday. The 50 day moving average is $9.28 followed by the 200 at a low of $8.10.,
If this isn't a SELL – what is ,
Is there more to come … ,
VSTM just “trugs” along in the preliminary stages of clinical development with twists and turns but nothing that upsets the apple cart – but great cash position!,
$0.01 is dribble. A little early for an “Atta boy.” But,
$190 M contingent payments of another $190 M…or $12.97 with terms of: $1.50 in cash up front and 0.2482 of a WMGI share (for total $6.47); 1 contingent value right (CVR) for additional $6.50 cash payable upon FDA approval of BMTI’s Augment Bone Graft an,
$4.5 M in restricted common stock and $6 M through the issuance of an 8 amortizing redeemable convertible debenture that matures 6/1,
1/18/13 at $0.62. It is probably an appreciable release but,
10 M shares and warrant Offering at $2.10,
A challenge to FDA’s Medical Device Authority … ,
a lot off issues – trials,
A “good to great” clean-up year to … position NBS for the future and specifically that Suzhou Erye is gone replaced by cash,
A “Strong BUY” and a price target of $3.00 for end of year FY12. ,
ACT will pay $12.5 M to the investors,
ACTC – the “whirling dervish” of RegMed companies.Can anyone take responsibility to make ACTC a real company – that has good science,
Advances in Autologous Whole Blood and Bone Marrow Separation ,
ALD-401 Safety Data presented at the World Stroke Congress in Brazil,
An actionable release – based on increased revenue capacity. CMXI closed at $0.60 and could add $0.05 to $0.10 to their share price with this CE Mark.,
An overnight deal in a negative surprise – the after-market has been selling off the share to the tune of $2.88 … from the close of $3.32.,
and their owners are willing to spend “unlimited” amounts of money on their health care,
Another significant milestone. The Erye divestiture brings non-dilutive capital that bolsters cash position,
anticipated IND filing and clinical data.,
As usual $0.04 or -3.05 to $1.27. So hold on … still a “Speculative BUY” … but,
ASTM,
ASTM has “spit the chew” of investor sentiment with investors having NO choice but to allow the new coach to yank the failing seasoned veteran with a rookie reliever . Tough and painful but not surprising with the RegMed,
ATHX,
ATHX does have a 17 M share offering coming … and the stock has been trading $0.01 to $1.22.,
Bio-preservation Technology Recognized by 50 Client usage,
BioTime (NYSE MKT: BTX) proposes stem cell assets acquisition deal – Issues Open Letter to Shareholders of Geron (GERN),
BLFS,
BLFS closed on Friday at $0.32 up $0.04 from $0.028 on 1/31/13.,
Breakdown of Q3/12 Achievements and Highlights and Results -NBS can break the $1.00 trend line by Q1/13. NBS is up $0.03 or 4.61 to $0.669.,
Breaking down Q3/12 Results and a "BUY" on no legal fanfare on Prochymal worldwide rights,
BTX closed at $3.97 on 4/6/13 and is DOWN -$0.01 or -0.25 to $3.96. BTX has been flip-flopping since the 26 of April on small to moderate volumes undermining the 52 week high of $5.07. A HOLD.,
cancellation of options,
Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies approved in Japan …,
cash,
CEO retires,
CMXI closed at $0.47 on 5/9/13. The 50 day moving average is $0.50 compared with the 200 day of $0.63 – the needle needs to be pushed! Investors should compare CMXI to Cytori (CYTX) who is trading at $2.59 as a good hybrid comparable. Let’s watch the stat,
collaboration and reverse split ,
Collaboration as HypoThermosol® Media Demonstrates Improved Storage with Exclusive Distribution Rights for Cellenergy™ Hair Graft Storage Additive,
Collaboration with Genzyme/Sanofi Ended ,
comprised of $2 M in cash,
Contract by BARDA to Develop Cell Therapies for Thermal Burns Combined with Radiation Injury – Strong BUY – Stock UP $0.54 or 13.99 to $4.40,
CYTX,
CYTX closed at $2.52 and is UP $0.04 or 1.599 – expect small volume but a penny or two on a fastly closing Holy week.,
CYTX closed at $2.93 up $0.08 or $2.63 . A “BUY” with expectation of a $0.10 to $0.20 pop in the next week.CYTX Q4 EPS of -$0.06 beats by $0.10. Revenue of $4.3 M beats by $0.2 M. CYTX made substantial progress in 2012 .,
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.




















View Henry McCusker's Instablogs on:
NeoStem (NYSE MKT: NBS) Swatting “The Fly On The Wall. Com”
No new securities are being offered ..contrary to the "Fly" non-article
NeoStem is … NOT … engaged in a new financing as reported by "The Fly on the Wall.com … Get the facts straight - they just finished one for $10.7 M in proceeds.
This registration statement was merely a renewal of an outstanding registration statement that covered the potential issuance of shares underlying warrants that were issued 3 years ago and remain outstanding.
NBS has an existing "shelf" registration statement on Form S-3, File No. 333-166169, that was declared effective on May 11, 2010 and which expires on May 11, 2013 pursuant to Rule 415(a)(5) under the Securities Act.
NBS filed … this new Registration Statement for the sole purpose of ensuring that an effective Registration Statement covers the exercise of such previously issued November 2010 $1.85 Warrants and Series E Warrants.
The Bottom Line: What the "hell" is this …!!! If NBS … were … to sell … any securities being registered, NBS would identify this event! The underlying shares were previously registered but the registration statement expired under relatively recent SEC rules needed to be refreshed. So bless me father in public confessional for using bad words to tell the truth!
NBS closed at $0.53 DOWN a penny from Wednesday.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Cytori (CYTX) Q1/13 Results – BUY
Net loss was $7.7 million, or ($0.11) per share
Net loss was $7.7 million, or ($0.11) per share for Q1/13 compared to $9.3 million, or ($0.16) per share, in Q1/12.
Revenues were $3.8 million, compared to $1.5 million in Q1/12. Product and government contract revenues were $1.9 million, compared to $1.5 million for Q1/12. Government contract revenues were $500 K related almost entirely to work performed under the BARDA contract, for which there were no comparable revenues recognized in Q1/12. Additionally, $1.8 million in revenue was recognized for services performed in relation to the JV with Olympus and the Senko distribution agreement. During Q1/13, CYTX terminated the Senko distribution agreement and reacquired from Senko the rights to SurgiWrap in Japan. Gross profit was $600 K, or 46%, compared to $600 K, or 42%, in Q1/12.
R&D expenses were $3.7 million compared to $2.8 million in Q1/12. The planned increase in R&D expenses is mostly related to services performed under the BARDA contract, in addition to clinical trial costs. SG&A expenses were $6.1 million compared to $6.3 million in Q1/12. Total operating expenses were $9.739 million versus 8.996 million in Q1/12 with an operating loss of (-6.737) million versus (-8.365) million. Shares used in computing the net loss in Q1/13 were 66.99 million compared with 57.48 million in Q1/12.
Guidance: CYTX reiterates guidance for the year of $15 million of product and contract revenue. Gross margins are expected to increase substantially in the second half of 2013 as increased second half revenues are realized. CYTX's core milestones for the next 12 months include the following:
Q1/13 Highlights:
The Bottom Line: CYTX closed at $2.60 UP +$0.04 or +1.56% to $2.60 and is DOWN in the after-market -$0.01 or -0.38% to $2.59. I believe this was one of the most informative Q reporting with no whining aspects of beginning the year compared to a few of the reporting companies.
CYTX reduced near and long-term liabilities in Q1/ by approximately $5.8 million. A substantial portion of its recent and projected cash needs relate to principal payments on its existing term loan. CYTX is in discussions with its lender group to extend the term of the loan and defer principal payments to coincide with anticipated product sales, government contract payments, and other potential cash milestones.
Also, consider the positives of CYTX in relation to the RegMed sector: completion of enrollment in ATHENA, successful execution of the BARDA contract deliverables, and growth in total revenues.
CYTX's product revenues were more heavily weighted by orders from Japan.This is driven in Japan based on the recent Class I approval and in Europe by the Celution® System CE Mark for intravascular delivery and tissue ischemia.
For the remainder of 2013, it is expected that product revenue growth will be driven by expanded research and general clinical use based on recent regulatory approvals in Japan and the EU.
Another positive, CYTX is seeing growing interest in the number of investigator-initiated studies, the number of multi-center studies and the number of patients anticipated to be treated in those trials. Financially, these trials are funded primarily by government grants or funds from specific healthcare institutions. Recently, an approximate $5 million grant from the Ministry of Health, Labor and Welfare (MHLW) in Japan was issued to support a multi-center trial that could lead to approval and reimbursement for cell therapy for stress urinary incontinence.
In Europe, CYTX has been informed by an investigator in France that an ongoing pilot study in patients with hand complications from scleroderma is being considered for a multi-center trial based on encouraging preliminary results.
The Puregraft® product line continues its positive sales trends. Record Puregraft® revenues were reported with growth in both sales and units shipped in sequential quarters as well as quarter over year ago quarter. This trend reflects the increasing demand for this product as well as the overall growth in fat grafting among plastic and reconstructive surgeons.
CYTX expects to accelerate Puregraft® sales with the launch of an important product line extension later this year, targeting a significant market for small volume fat grafting procedures.
CYTX has finalized an agreement with Olympus Corporation to acquire all of Olympus' rights to the Olympus-Cytori Joint Venture, including Celution® product manufacturing and patent rights and eliminating any royalty obligations to the Joint Venture.
As part of the agreement, the Olympus-Cytori Joint Venture will return all rights to Cytori at closing in exchange for alternative payment or call options including: $4.5 million within 1 year or $6 million within 2 years <some of which is part of dollars already held>.
I consider CYTX a … BUY … and value <that they haven't driven to the offering window> reducing costs and decreasing the net losses while structuring their guidance to highlight their current service agreements with BARDA and other sources. Regaining full control of manufacturing rights provides CYTX with greater flexibility on the manufacturing process and associated costs, enables higher margins, and speeds the transition to the smaller next-generation system although at a I believe a … minimal cost as associated with the dollars invested over the development and past partnered agreement.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Pluristem (PSTI) Develops PLX-RAD Cells For Use In Hematology
Enhancing Hematopoietic Stem Cell Engraftment will be the first indication
PSTI has identified its first clinical indication in the hematology field for its Placental eXpanded (PLX) RAD cells for the enhancement of the engraftment of Hematopoietic Stem Cells (HSC) in patients experiencing a delay or failure of their bone marrow transplant (BMT).
This follows Pluristem's completion of additional pre-clinical studies showing promising results for PLX-RAD for this indication. PLX-RAD is currently being evaluated by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S.NIH, in models of the acute radiation syndrome (ARS).
The Bottom Line: PLX-RAD cells have been shown to have an immunomodulatory effect via the secretion of cytokines and proteins that are known to stimulate Hematopoietic Stem Cells (HSC) to enhance the production of white blood cells, red blood cells and platelets. There was also evidence of a significant improvement in the recovery of these three blood lineages in bone marrow deficient animals compared to control animals.
PSTI closed at $2.97 and is UP +$0.09 or +3.03% to $3.06 in the pre-market. I would add another $0.05-$0.07 to the current movement by the close of day. A "BUY".
The essential element in BMT is the transplantation of Hematopoietic Stem Cells (HSC), the precursor of the formed elements of the blood (red cells, white cells and platelets). BMT is commonly used in the treatment of hematological malignancies to reconstitute the patient's bone marrow after their diseased marrow is eradicated with chemo or radiotherapy. Approximately 15% of patients undergoing BMT will either have a significant delay or failure to engraft the HSCs contained in the BMT, a condition that is life threatening, expensive and often requires the continued support of the patient with blood products. According to the National Marrow Donor Program, an estimated 25,000 allogeneic bone marrow transplants are performed annually worldwide. Approximately 15% of these patients will either have a delay or failure to engraft the HSCs, resulting in a condition that is life threatening, expensive and often requires the continued support of the patient with blood products. PLX-RAD may be beneficial to these patients.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.